A novel Gboxin analog induces OXPHOS inhibition and mitochondrial dysfunction-mediated apoptosis in diffuse large...

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin's lymphoma with limited treatment options.
• Existing therapies for DLBCL have moderate efficacy and significant limitations.
• There is a critical need for novel and more effective therapeutic agents for DLBCL.

Purpose of the Study:

• To design and synthesize novel Gboxin analogs as potential inhibitors of oxidative phosphorylation (OXPHOS).
• To evaluate the efficacy and mechanism of action of a specific analog, 5d, against DLBCL cells.
• To explore 5d as a potential alternative drug candidate for DLBCL treatment.

Main Methods:

• Synthesis of 21 Gboxin analogs with amide and ester moieties.
• In vitro screening of analogs for selective anticancer activity, particularly against DLBCL cells.
• Detailed investigation of 5d's effects on DLBCL cell proliferation, cell cycle, apoptosis, and underlying molecular mechanisms.

Main Results:

• Compound 5d demonstrated selective toxicity towards cancer cells, notably DLBCL cells.
• 5d exhibited potent inhibition of DLBCL cell proliferation and induced cell cycle arrest with an IC50 below 1 µM.
• 5d effectively induced time- and dose-dependent apoptosis in DLBCL cells, surpassing Gboxin and VP16 in potency.
• Mechanistic studies revealed that 5d stimulates metabolic stress, leading to OXPHOS inhibition, inflammation, DNA damage, and mitochondrial dysfunction.

Conclusions:

• Compound 5d shows significant potential as an alternative therapeutic agent for diffuse large B-cell lymphoma.
• The mechanism of action involves inducing metabolic stress and subsequent cellular damage in DLBCL cells.
• Further development of 5d could lead to novel treatment strategies for DLBCL patients.